News

2025.04.24Remiges Ventures Launches RDiscovery Fund: Incubating Drug Discovery Seeds

2025.02.13Restore Vision, one of Remiges' portfolio companies, announced the first patient dosed in Phase I/II clinical trial of RV-001 for gene-agnostic retinitis pigmentosa

2025.02.06InFlectis BioScience, one of our portfolio companies, announced today promising Phase 2a clinical study results for IFB-088 in patients with bulbar-onset ALS

2024.10.24KisoJi Biotechnology, one of Remiges' portfolio companies, has entered a strategic collaboration agreement with Cancer Research UK on KisoJi's unique single-domain antibody program, KJ-103 targeting TROP2 for the treatment of solid tumors

2024.10.08Qinotto, one of Remiges' portfolio companies, has entered a research collaboration and license agreement with Lilly on a novel shuttle program for delivering novel agents beyond blood-brain barrier for the treatment of neurodegenerative diseases

2024.09.26OMEICOS, a portfolio company of Remiges Ventures, completes enrollment of PMD-OPTION study in primary mitochondrial disease

2024.09.10LUCA Science, a portfolio company of Remiges Ventures, has published significant research findings in Nature Metabolism: The study highlights how mitochondria transfer-based therapies can reduce morbidity and mortality in Leigh syndrome

2024.05.10ENB Therapeutics, one of Remiges Ventures’ portfolio companies, announced clinical collaboration between Coherus and the Cancer Research Institutes using ENB-003 for the treatment of ovarian cancer

2024.04.30InFlectis BioScience, a portfolio company of Remiges Ventures in France, was awarded a grant from the National Multiple Sclerosis Society to advance IFB-048 preclinical development in multiple sclerosis. The research will be performed by Prof. Brian Popko of Northwestern University

2024.03.04Glycomine, one of Remiges Ventures’ portfolio companies, announced encouraging efficacy data from ongoing Phase2 clinical study in PMM2-CDG

2024.01.31InFlectis BioScience, a portfolio company of Remiges Ventures in France, completed enrollment of patients for the Phase 2 trial of IFB-088 for the treatment of bulbar onset Amyotrophic Lateral Sclerosis, with initial results anticipated later this year

2024.01.16Cyrano Therapeutics, a portfolio company of Remiges Ventures, secures $9.0 million Series B financing to advance clinical development of CYR-064 for treatment of Post-Viral Smell Loss

2024.01.03InFlectis BioScience, a portfolio company of Remiges Ventures in France, was awarded a grant from the ALS Association to advance the ongoing ALS clinical trial with the support of the IRCCS Carlo Besta Neurological Institute

2023.12.01Imel Therapeutics KK, one of Remiges Ventures' portfolio companies, has been selected for the "Drug Discovery Venture Ecosystem Enhancement Project" by AMED, which provides grants

2023.11.09ENB Therapeutics, one of Remiges Ventures’ portfolio companies, announced its Phase1b study results of ENB-003

2023.08.25Remiges’ portfolio company Phost’in Therapeutics SAS and Taiho Pharmaceuticals have announced an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430

2023.07.28Restore Vision, Inc., one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem

2023.06.05Remiges Ventures led the 1st close of Series A round for Restore Vision, Inc. in Japan

2023.03.31Capacity Bio, For Which Remiges Ventures Was Founding Investor, Raised $35M 

2023.01.04Remiges Portfolio Companies Raised In Aggregate More Than $145 million in 2022

2022.12.23Immunohelix Co., Ltd, one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem

2022.09.26Remiges Ventures led the Series A round of finance for Kupando GmbH in Germany

2022.08.03Remiges Ventures led the Series A round of finance for Immunis in California

2022.06.30Remiges selected as Certified VC by the AMED Strengthening Program for Pharmaceutical Venture Ecosystem

2022.06.06Luca Science, one of our portfolio companies in Japan, closed a $30.3M Series B round

2022.06.02Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168

2022.03.08Digestome Therapeutics announced first patient enrolled in Phase 1 clinical trial of DGX-001

2022.02.04Remiges Ventures co-led the Series Seed round of finance for Restore Vision, Inc. in Japan

2022.01.10Inflects Bioscience receives approval from French regulatory authority to conduct a Phase 2 Clinical Trial for IFB-088 for ALS

2021.06.23Remiges joined Series B Round of Glycomine in California

2021.05.27The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports

2021.04.09Remiges Ventures Closes Second Fund with $95 million; Launches RDiscovery Incubator

2020.12.10Remiges led the Series A round of finance for Cyrano Therapeutics in Washington D.C.

2020.07.09
Remiges co-led the Series A round of finance for Tranquis Therapeutics in California

2020.04.20
Remiges led the Series A round of finance for Phost'In Therapeutics in France

2020.03.01
Remiges Welcomes New Team Member

2020.01.07
Inflectis BioScience announced successful completion of Phase 1 clinical trial of IFB-088

2020.01.01
Remiges Welcomes New Team Member

2019.04.01
Remiges created our third seed stage company based on intellectual properties from the Japanese academia

2019.04.01
Remiges created our second seed stage company based on intellectual properties from the Japanese academia

2019.02.04
ENB Therapeutics, one of the Remiges Ventures' portfolio companies, announced its clinical trial collaboration with Merck

2018.11.02
OMEICOS Therapeutics, one of the Remiges Ventures' portfolio companies, closed its €17m Series C financing

2018.09.21
Remiges led the Series A round of finance for ENB Therapeutics in New York

2018.06.27
Remiges created a de novo company based on intellectual properties from a national university in Japan

2018.06.13
Remiges joined Series A1 Round of KisoJi Biotechnology in Montreal Canada

2017.10.04
Remiges joined Extension of Series B Round of Omeicos Therapeutics to expand its technology into Ophthalmology

2017.06.27
Remiges led the Series A round of finance for Mitoconix Bio in Israel

2017.03.06
Remiges Welcomes New Partner

2017.02.14
The final closing of Remiges BioPharma Fund achieved raising a total $80 million

2016.06.01
Remiges co-led the Series A round of finance for InFlectis BioScience in France

2016.04.19
Remiges selected as Certified VC by the NEDO Technology-based Startup Support Program